Cytokinetics Announces Three Upcoming Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at American Col...
May 10 2021 - 4:00PM
Cytokinetics, Incorporated (Nasdaq:CYTK) today announced three
presentations at the American College of Cardiology 70th Annual
Scientific Session & Expo (ACC.21) taking place online from May
15, 2021 - May 17, 2021. Included among these presentations will be
a secondary analysis of GALACTIC-HF (
Global
Approach to
Lowering
Adverse
Cardiac Outcomes
Through
Improving
Contractility in
Heart
Failure) assessing the effect of omecamtiv
mecarbil on clinical outcomes in relationship to patient baseline
ejection fraction, in a Late Breaking Clinical Trial session.
Late Breaking Clinical Trial
Session
Title: 410-16 Impact of
Ejection Fraction on the Therapeutic Effect of Omecamtiv Mecarbil
In Patients with Heart Failure and Reduced Ejection Fraction: A
Secondary Analysis From GALACTIC-HF (Global
Approach to Lowering
Adverse Cardiac Outcomes
Through Improving
Contractility in Heart
Failure) Presenter: John
Teerlink, M.D., Professor of Medicine, University of California San
Francisco, Director of Heart Failure, San Francisco Veterans
Affairs Medical Center and Executive Committee Chair,
GALACTIC-HFDate: May 17, 2021Session
Title: Late-Breaking Clinical Trials IVSession
Time: 8:00 – 9:15 AM ETPresentation Time:
9:00 – 9:10 AM ET
Poster Presentations
The following posters will be available on
demand for registered attendees beginning on May 15, 2021 at 8:00
AM ET.
Title: Clinical Profile of
Obstructive Hypertrophic Cardiomyopathy in a Nationwide Patient
CohortPresenter: Michael Butzner, DrPH, MPH,
Health Economics & Outcomes Research,
CytokineticsSession Title: 2194 – Heart Failure
and Cardiomyopathies: Clinical Science 2
Title: Ninety-Day Episode of
Care Spending Following Heart Failure Hospitalization Among
Medicare BeneficiariesPresenter: Samuel Reinhardt,
M.D., Cardiovascular Medicine, Yale New Haven
HospitalSession Title: 2200 – Heart Failure and
Cardiomyopathies: Population Science 2
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and next-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is engaging with regulatory authorities
in preparation for a U.S. NDA submission of omecamtiv mecarbil, its
novel cardiac muscle activator, following positive results from
GALACTIC-HF, a large, international Phase 3 clinical trial in
patients with heart failure. Cytokinetics is conducting
METEORIC-HF, a second Phase 3 clinical trial of omecamtiv mecarbil.
Cytokinetics is also developing CK-274, a next-generation cardiac
myosin inhibitor, for the potential treatment of hypertrophic
cardiomyopathies (HCM). Cytokinetics is conducting REDWOOD-HCM, a
Phase 2 clinical trial of CK-274 in patients with obstructive HCM.
Cytokinetics is also developing reldesemtiv, a fast skeletal muscle
troponin activator for the potential treatment of ALS and other
neuromuscular indications following conduct of FORTITUDE-ALS and
other Phase 2 clinical trials. The company is preparing for the
potential advancement of reldesemtiv to a Phase 3 clinical trial in
ALS. Cytokinetics continues its over 20-year history of pioneering
innovation in muscle biology and related pharmacology focused to
diseases of muscle dysfunction and conditions of muscle
weakness.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements and claims
the protection of the Act's Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to the GALACTIC-HF clinical trial,
statements relating to the potential benefits of omecamtiv
mecarbil. Cytokinetics' research and development activities; the
design, timing, results, significance and utility of preclinical
and clinical results; and the properties and potential benefits of
Cytokinetics' other drug candidates. Such statements are based on
management's current expectations, but actual results may differ
materially due to various risks and uncertainties, including, but
not limited to, potential difficulties or delays in the
development, testing, regulatory approvals for trial commencement,
progression or product sale or manufacturing, or production of
Cytokinetics' drug candidates that could slow or prevent clinical
development or product approval; Cytokinetics' drug candidates may
have adverse side effects or inadequate therapeutic efficacy; the
FDA or foreign regulatory agencies may delay or limit Cytokinetics'
ability to conduct clinical trials; Cytokinetics may be unable to
obtain or maintain patent or trade secret protection for its
intellectual property; standards of care may change, rendering
Cytokinetics' drug candidates obsolete; and competitive products or
alternative therapies may be developed by others for the treatment
of indications Cytokinetics' drug candidates and potential drug
candidates may target. For further information regarding these and
other risks related to Cytokinetics' business, investors should
consult Cytokinetics' filings with the Securities and Exchange
Commission.
Contact:CytokineticsDiane WeiserSenior Vice
President, Corporate Communications, Investor Relations(415)
290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2024 to May 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From May 2023 to May 2024